Chinese authority suspends import, sale, and use of Dr Reddy's Labs Atomoxetine Hydrochloride Capsules
Through a recent BSE filing, Dr Reddy's Labs has informed that the National Medical Products Administration, China (NMPA) has suspended the import, sale, and use of the Company's Atomoxetine Hydrochloride Capsules.
NMPA China recently conducted a remote inspection of the Company’s formulations manufacturing facility (FTO-3) for Atomoxetine Hydrochloride Capsules, and concluded that the production quality management of Atomoxetine Hydrochloride Capsules does not meet the requirements of China's "Good Manufacturing Practice for Drugs (Revised in 2010)".
Atomoxetine Hydrochloride Capsules is a medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children and adults.
Further, National Drug Joint Procurement Office, China (NDJPO), having considered the said order of the NMPA, has decided to cancel Dr. Reddy's Laboratories Ltd.'s Atomoxetine Hydrochloride Capsules “won” status and list the company on the "Violation List", suspending the company's eligibility to participate in China'snational centralized drug procurement activities from August 30, 2024 to February 28, 2026.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.